Modern blood-thinning drugs (known as NOACs) reduce the risk of serious bleeding by up to 45% compared to the traditional drug Waran (warfarin) in the treatment of blood clots in the legs and lungs. All according to a comprehensive and long-term study conducted at the University of Gothenburg.
Prior to the introduction of NOACs, studies on short-term treatment regimens showed that such treatment reduced the risk of bleeding compared to Waran. This has resulted in an increasing number of patients who have had a bloodExtensive Swedish study
For the first time, researchers have now examined the risk of bleeding in both short-term and extended treatment of blood clots in the legs and lungs in a nationwide study in Sweden. The study demonstrates the advantages of NOACs, in particular the substance, which is marketed under the brand name Eliquis. The study shows that the risk of serious bleeding is 45% lower with apixaban compared to warfarin.
The study's lead author, Katarina Glise Sandblad, is a doctoral student at Sahlgrenska Academy at the University of Gothenburg as well as a specialist doctor at Sahlgrenska University Hospital. The results of the study are published in the"We see that apixaban is associated with a lower risk of bleeding in both the short and the long term compared to warfarin. The short-term risk of bleeding is also lower compared to rivaroxaban , another pharmaceutical substance in the NOAC family.
In conclusion, the study shows that apixaban was associated with the lowest risk of bleeding during the first six months of treatment. Rivaroxaban also had a lower risk of bleeding than warfarin, although not as low as apixaban. The difference between apixaban and rivaroxaban was not statistically significant in extended treatment as both of these pharmaceutical substances were associated with a relatively low risk of bleeding .
"Today, if a patient is prescribed Waran for the first time by their doctor, in the vast majority of cases it is for good reason, although it can be a good idea for the patient to ask about that reason. This applies to patients withas well as those with blood clots in the legs and lungs.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Switching to NOACs in frail elderly patients with atrial fibrillation increases bleeding riskSwitching vitamin K antagonist (VKA) treatment to a non-vitamin K antagonist oral anticoagulant (NOAC) in frail elderly patients with atrial fibrillation is associated with more bleeding complications compared to continuing VKA treatment.
Lire la suite »
Dad-of-six collapses and dies after helping son move into university dormJeremy Tillman, 45, collapsed while moving his son into an Arkansas State University dormitory.
Lire la suite »
Study discovers method to classify febrile illness with a single blood sampleResearchers trained machine learning (ML) models to analyze RNA molecular signatures in patients’ blood.
Lire la suite »
Playing lullabies reduces babies' pain during minor procedures like blood tests, study findsResearchers suggest soothing music could usefully be employed in hospitals around the world for pain relief in babies
Lire la suite »
CapCut breaths life into new-wave blogging for modern businessesFind out how to take your blog to the next level with CapCut
Lire la suite »